Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

@article{Marks2019TopicalAT,
  title={Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris},
  author={Dustin H. Marks and Sonya Prasad and Brianna de Souza and Laura J. Burns and Maryanne M. Senna},
  journal={American Journal of Clinical Dermatology},
  year={2019},
  volume={21},
  pages={245-254}
}
Androgenetic alopecia (AGA) and acne vulgaris are two conditions commonly seen by dermatologists. Androgens and the androgen receptors play an essential role in the manifestation of both conditions, and some systemic therapies function by interfering in this pathway. The use of topical antiandrogen therapies has gained traction in recent years due to their potential efficacy in treating AGA and acne vulgaris, as well as their reduced adverse effects compared with systemic drugs. This review… 
Clascoterone: First Approval
TLDR
The milestones in the development of clascoterone leading to this first approval for the topical treatment of acne vulgaris are summarized.
Updated Treatment for Acne: Targeted Therapy Based on Pathogenesis
TLDR
Future treatment for acne should embrace approaches that target the main etiological factors of acne, and specific emphasis on aggressive treatment in the acute inflammatory phase to reduce the likelihood of scarring and other clinical sequelae, such as pigmentary changes would be highly desirable.
A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
TLDR
The results of this concentration‐QTc analysis demonstrate that cortexolone 17α‐propionate and its metabolite/degradation product had no effect on the QTc interval in the concentration range tested.
Determination and Correlation of the Solubility of Cyproterone Acetate in Fourteen Pure Solvents and Water + Ethanol Mixed Solvents at Temperatures from 273.15 to 318.15 K
The solubility of cyproterone acetate in 14 pure solvents, such as methyl tert-butyl ether, xylene, 1-butanol, 1-propanol, tetrahydrofuran, ethanol, ethyl acetate, isopropanol, acetone, acetonitril...

References

SHOWING 1-10 OF 83 REFERENCES
A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women.
TLDR
Preliminary results on the use of topical FNS are limited, but safe and promising, and continued research into drug-delivery, ideal topical concentration and application frequency, side effects, and use for other alopecias will help to elucidate the full extent oftopical FNS' use.
Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course
TLDR
The clinical outcome, in terms of both hair regrowth and balding areas reduction, seems to be encouraging, in the absence of either any evidence of percutaneous absorption of finasteride, or local/systemic untoward effects.
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta‐analysis
TLDR
This meta‐analysis strongly suggests that minoxidil, finasteride, and low‐level laser light therapy are effective for promoting hair growth in men with androgenetic alopecia and that minxidil is effective in women with androgensetic alipecia.
Ketoconazole in the treatment of acne in women.
TLDR
Ketoconazole, an oral imidazole antifungal drug, is a potent inhibitor of testosterone synthesis that has been recently used to induce and maintain a remission in patients with advanced prostatic cancer.
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men
TLDR
Evidence is presented to support the hypothesis that ketoconazole 2% shampoo has a local disruption of the DHT pathway and could lead to a more complete inhibition of DHT and thus better treat AGA.
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men.
TLDR
Evidence is presented to support the hypothesis that ketoconazole 2% shampoo has a local disruption of the DHT pathway and could lead to a more complete inhibition of DHT and thus better treat AGA.
Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
TLDR
Clascoterone was found to inhibit AR-regulated transcription in a reporter cell line with similar efficacy to the 5α-reductase inhibitor, finasteride, and may be an excellent candidate to be the first topical antiandrogen for treating androgenetic alopecia.
Treatment of hyperandrogenic alopecia in women.
TLDR
Flutamide at a dose of 250 mg daily induced a modest improvement in alopecia after 1 year, whereas cyproterone acetate and finasteride were not effective.
Ketoconazole Shampoo: Effect of Long-Term Use in Androgenic Alopecia
TLDR
Comparative data suggest that there may be a significant action of KCZ upon the course of androgenic alopecia and that Malassezia spp.
Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia.
TLDR
The therapeutic effects of bothfinasteride gel and finasteride tablet were relatively similar to each other, and Serial measurements indicated a significant increase in hair counts and terminal hair counts between the two groups.
...
1
2
3
4
5
...